Pacific Edge Ltd (PEB)
Australian Securities Exchange · Australia · prices in AUD · close of 19 Oct 2026
Key indicators
| Last close | AUD 0.190 |
|---|---|
| 52-week range | 0.085 – 0.265 |
| Return, 1 month / 3 months | −9.5% / −19.1% |
| Return, 1 year / 3 years | +93.9% / −86.2% |
| Trend | Below its 200-day average |
| RSI (14) | 33 |
| Volatility (1 year) | 88.1% |
| Worst drawdown (1 year) | -34.1% |
| Average daily value traded | 0.01M AUD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Pacific Edge is a New Zealand cancer diagnostics company based in Dunedin. It develops and markets urine-based molecular tests, chiefly under the Cxbladder name, which help clinicians assess patients with blood in the urine and monitor people for bladder cancer. Its customers are urologists, hospitals and healthcare providers, mainly in New Zealand and the United States, who use the tests to support decisions about further investigation and follow-up care.
On this site Pacific Edge Ltd appears as a stock on the Australian Securities Exchange (Australia), code PEB, with prices in Australian dollars (AUD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Pacific Edge Ltd (PEB) trades on the Australian Securities Exchange in Australia. It last closed at AUD 0.190 on 19 October 2026.
Its price-based Market X-Ray is 55 out of 100 (a fair price profile), ranking 788 of 1,815 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 93.9% and over the last three months it fell 19.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 76 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | -0.5% | ||
| From 52-week high | -26.9% | ||
| Momentum | 53 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -19.1% | ||
| 6-month return | 8.6% | ||
| 12-month return, skipping the last month | – | ||
| Stability (higher is calmer) | 57 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 88.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -34.1% | ||
| Liquidity | 21 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.01M AUD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +0.0% |
|---|---|
| 1 month | −9.5% |
| 3 months | −19.1% |
| 6 months | +8.6% |
| 1 year | +93.9% |
| 3 years | −86.2% |
| 5 years | – |
Signals
| 50-day / 200-day average | 0.212 / 0.191 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.005 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.